The strength of our study was that here we demonstrated for the potential application of blood metabolomes as non-invasive markers for evaluating the severity and prognosis of doxorubicin-induced cardiotoxicity, both in HER2-positive and HER2-negative breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.